Stimulator of interferon genes protein
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count | Chain D； UniProt 155–379 Chain E； UniProt 155–379 | Mutation：T376E, F378M,S379W | Serine/threonine-protein kinase TBK1 × 2 （Q9UHD2） BX7 N-(3-{[5-iodo-4-({3-[(thiophen-2-ylcarbonyl)amino]propyl}amino)pyrimidin-2-yl]amino}phenyl)pyrrolidine-1-carboxamide × 2 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；0.8 M (NH4)2SO4, 0.1 M BIS-TRIS pH 5.5 and 1% PEG3350 | Resolution 3.40 Å R-free 0.258 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 6O8B | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 4EF4 Crystal structure of STING CTD complex with c-di-GMP Deposited 2012-03-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
139–379（241 aa）
Fragment：C-TERMINAL DOMAIN
Chain B
139–379（241 aa）
Fragment：C-TERMINAL DOMAIN
|
Not recorded | C2E 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) × 1 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；14.4%(w/v) PEG8000, 0.08M Cacodylate, 0.16M calcium acetate, 20%(v/v) glycerol, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.15 Å R-free 0.257 |
| 4EF5 Crystal structure of STING CTD Deposited 2012-03-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
139–379（241 aa）
Fragment：C-TERMINAL DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；14.4%(w/v) PEG8000, 0.08M Cacodylate, 0.16M calcium acetate, 20%(v/v) glycerol, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.45 Å R-free 0.288 |
| 4EMT Crystal Structure of human STING bound to c-di-GMP Deposited 2012-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：UNP residues 155 - 341
Chain B
155–341（187 aa）
Fragment：UNP residues 155 - 341
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | C2E 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) × 1 CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；28% PEG400, 0.2M CaCl2, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.50 Å R-free 0.210 |
| 4EMT Crystal Structure of human STING bound to c-di-GMP Deposited 2012-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
155–341（187 aa）
Fragment：UNP residues 155 - 341
Chain B
155–341（187 aa）
Fragment：UNP residues 155 - 341
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | C2E 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) × 2 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；28% PEG400, 0.2M CaCl2, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.50 Å R-free 0.210 |
| 4EMU Crystal structure of ligand free human STING Deposited 2012-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：UNP residues 155 - 341
Chain B
155–341（187 aa）
Fragment：UNP residues 155 - 341
|
Not recorded | CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1 M HEPES, pH 8.5, 28% PEG400, 0.2M CaCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å R-free 0.248 |
| 4EMU Crystal structure of ligand free human STING Deposited 2012-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
155–341（187 aa）
Fragment：UNP residues 155 - 341
Chain B
155–341（187 aa）
Fragment：UNP residues 155 - 341
|
Not recorded | CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1 M HEPES, pH 8.5, 28% PEG400, 0.2M CaCl2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å R-free 0.248 |
| 4F5D ERIS/STING in complex with ligand Deposited 2012-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
141–379（239 aa）
Fragment：UNP residues 141-379
Chain B
141–379（239 aa）
Fragment：UNP residues 141-379
|
Mutation：G230A Mutation：G230A | C2E 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) × 1 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；289 K；0.025M MgSO4, 0.05M Tris-HCl pH 8.5, 1.8M AmSO4, VAPOR DIFFUSION, SITTING DROP, temperature 289K
|
Resolution 3.00 Å R-free 0.242 |
| 4F5E Crystal structure of ERIS/STING Deposited 2012-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
141–379（239 aa）
Fragment：UNP residues 141-379
|
Mutation：G230A | EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；25.0% PEG 3350, 0.1M Bis-tris pH 6.5, 0.2M NH4-acetate, 5% Glycerol, 0.025% Dichloromethane, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.60 Å R-free 0.255 |
| 4F5W Crystal structure of ligand free human STING CTD Deposited 2012-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
149–379（231 aa）
Fragment：UNP RESIDUES 149-379
|
Not recorded | CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.08M Sodium cacodylate pH 6.5, 0.16M Calcium acetate, 15% PEG 8000, 20% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.275 |
| 4F5Y Crystal structure of human STING CTD complex with C-di-GMP Deposited 2012-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
149–379（231 aa）
Fragment：UNP RESIDUES 149-379
Chain B
149–379（231 aa）
Fragment：UNP RESIDUES 149-379
|
Not recorded | CA CALCIUM ION × 2 C2E 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；15% PEG 8000, 0.08M sodium cacodylate pH6.5, 0.16M calcium acetate and 20% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.275 |
| 4F9E Cyclic di-GMP Sensing via the Innate Immune Signaling Protein STING Deposited 2012-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
139–379（241 aa）
Fragment：C-terminal Domain (unp residues 139-379)
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.75 Å R-free 0.258 |
| 4F9G Crystal structure of STING complex with Cyclic di-GMP. Deposited 2012-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
139–379（241 aa）
Fragment：C-terminal Domain (unp residues 139-379)
Chain C
139–379（241 aa）
Fragment：C-terminal Domain (unp residues 139-379)
|
Not recorded | C2E 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；289 K；12-15% PEG8000, 0.08 M sodium cacodylate pH 6.3-6.5, 0.16 M calcium acetate and 20% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.95 Å R-free 0.255 |
| 4KSY Crystal structure of STING in complex with cGAMP Deposited 2013-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
138–379（242 aa）
Fragment：UNP residues 138-379
|
Not recorded | 1SY cGAMP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；27% PEG 3,350, 0.1 M Bis-Tris, pH 6.8, 0.2 M NaCl, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.88 Å R-free 0.181 |
| 4LOH Crystal structure of hSTING(H232) in complex with c[G(2',5')pA(3',5')p] Deposited 2013-07-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：c-di-GMP-binding domain
Chain B
155–341（187 aa）
Fragment：c-di-GMP-binding domain
|
Not recorded | 1SY cGAMP × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；0.01 M NiCl2, 0.1 M Tris, 20% PEG2000, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.25 Å R-free 0.215 |
| 4LOI Crystal structure of hSTING(H232) in complex with c[G(2',5')pA(2',5')p] Deposited 2013-07-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：c-di-GMP-binding domain
Chain B
155–341（187 aa）
Fragment：c-di-GMP-binding domain
|
Not recorded | PO4 PHOSPHATE ION × 1 1YC 2-amino-9-[(1R,3R,6R,8R,9R,11S,14R,16R,17R,18R)-16-(6-amino-9H-purin-9-yl)-3,11,17,18-tetrahydroxy-3,11-dioxido-2,4,7,10,12,15-hexaoxa-3,11-diphosphatricyclo[12.2.1.1~6,9~]octadec-8-yl]-1,9-dihydro-6H-purin-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293 K；1.6 M NaH2PO4, 0.4 M Na2HPO4, 0.1 M phosphate-citrate, pH 4.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.89 Å R-free 0.199 |
| 4QXO Crystal structure of hSTING(group2) in complex with DMXAA Deposited 2014-07-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP residues 155-341)
|
Mutation：L222R, K224M, T229N, G230I, H232R, D237N, I244V | 1YE (5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.8；293 K；2 M LiCl, 10% PEG6000, 0.01 M CaCl2, 0.1 M Tris, pH 7.8, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.88 Å R-free 0.218 |
| 4QXP Crystal structure of hSTING(G230I) in complex with DMXAA Deposited 2014-07-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP RESIDUES 155-341)
Chain B
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP RESIDUES 155-341)
|
Mutation：G230I, H232R Mutation：G230I, H232R | 1YE (5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.1；293 K；0.2 M Li2SO4, 20% PEG 3350, 0.015 mM CYMAL-7, 0.1 M Tris, pH 8.1, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.51 Å R-free 0.239 |
| 4QXQ Crystal structure of hSTING(S162A/Q266I) in complex with DMXAA Deposited 2014-07-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP RESIDUES 155-341)
Chain B
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP RESIDUES 155-341)
|
Mutation：S162A, H232R, Q266I Mutation：S162A, H232R, Q266I | 1YE (5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.1；293 K；0.2 M Ca(Ac)2, 15% PEG3000, 0.01 M L-Proline, 0.1 M NaAc, pH 5.1, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.42 Å R-free 0.229 |
| 4QXR Crystal structure of hSTING(S162A/G230I/Q266I) in complex with DMXAA Deposited 2014-07-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP RESIDUES 155-341)
Chain B
155–341（187 aa）
Fragment：C-TERMINAL DOMAIN (UNP RESIDUES 155-341)
|
Mutation：S162A, G230I, H232R, Q266I Mutation：S162A, G230I, H232R, Q266I | 1YE (5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.1；293 K；0.2 M Ca(Ac)2, 15% PEG3000, 0.1 M LiCl, 0.1 M NaAc, pH 5.1, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.37 Å R-free 0.231 |
| 5BQX Crystal structure of human STING in complex with 3'2'-cGAMP Deposited 2015-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
138–379（242 aa）
|
Not recorded | 4UR 3'2'-cGAMP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.8；293 K；0.2 M ammonium acetate, 0.1 M trisodium citrate, pH 5.8, 25% PEG4000
|
Resolution 2.00 Å R-free 0.226 |
| 5JEJ Phosphorylated STING in complex with IRF-3 CTD Deposited 2016-04-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
342–379（38 aa）
Fragment：UNP residues 342-379
Chain D
342–379（38 aa）
Fragment：UNP residues 342-379
Chain E
342–379（38 aa）
Fragment：UNP residues 342-379
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.1 M Bis-Tris, pH 5.5, 200 mM MgCl2, 20% PEG 3350
|
Resolution 2.00 Å R-free 0.237 |
| 6CFF Stimulator of Interferon Genes Human Deposited 2018-02-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
139–379（241 aa）
|
Not recorded | 2BA (2R,3R,3aS,5R,7aR,9R,10R,10aS,12R,14aR)-2,9-bis(6-amino-9H-purin-9-yl)octahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8 ]tetraoxadiphosphacyclododecine-3,5,10,12-tetrol 5,12-dioxide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.2；285 K；Sodium citrate tribasic, PEG 3350, pH 8.2
|
Resolution 2.40 Å R-free 0.249 |
| 6CY7 Human Stimulator of Interferon Genes Deposited 2018-04-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
139–379（241 aa）
Fragment：UNP residues 139-379
|
Not recorded | 2BA (2R,3R,3aS,5R,7aR,9R,10R,10aS,12R,14aR)-2,9-bis(6-amino-9H-purin-9-yl)octahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8 ]tetraoxadiphosphacyclododecine-3,5,10,12-tetrol 5,12-dioxide × 2 IMD IMIDAZOLE × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；285 K；ammonium citrate tribasic, imidazole, PEG5000 MME
|
Resolution 2.20 Å R-free 0.258 |
| 6DNK Human Stimulator of Interferon Genes Deposited 2018-06-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
154–337（184 aa）
|
Not recorded | 1SY cGAMP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.7；285 K；Sodium sulfate, PEG 3350
|
Resolution 1.95 Å R-free 0.241 |
| 6MX0 Crystal structure of human STING apoprotein (G230A, H232R, R293Q) Deposited 2018-10-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：C-terminal domain
Chain B
155–341（187 aa）
Fragment：C-terminal domain
|
Mutation：G230A,H232R,R293Q Mutation：G230A,H232R,R293Q | CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；277 K；31.0 v/v PEG 400, 0.1 M Tris hydrochloride, 0.2 M calcium chloride
|
Resolution 1.73 Å R-free 0.220 |
| 6MX3 Crystal structure of human STING (G230A, H232R, R293Q) in complex with Compound 1 Deposited 2018-10-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Chain B
155–341（187 aa）
|
Mutation：G230A, H232R, R293Q Mutation：G230A, H232R, R293Q | K5P (3S,4S)-2-(4-tert-butylphenyl)-3-(4-methoxyphenyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid × 2 CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；33.0 v/v PEG 400
0.1 M Tris hydrochloride pH 8.0
0.2 M calcium chloride
|
Resolution 1.36 Å R-free 0.202 |
| 6MXE Crystal structure of human STING (G230A, H232R, R293Q) in complex with Compound 18 Deposited 2018-10-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Chain B
155–341（187 aa）
|
Mutation：G230A,H232R,R293Q Mutation：G230A,H232R,R293Q | K5S [(3S,4S)-2-(4-tert-butyl-3-chlorophenyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-fluoro-1-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl]acetic acid × 2 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；277 K；0.2 M CaCl2
29.0 v/v PEG 400
0.1 M TRIS
0.002 M DTT
|
Resolution 2.47 Å R-free 0.248 |
| 6O8C Crystal structure of STING CTT in complex with TBK1 Deposited 2019-03-09 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
342–379（38 aa）
Chain E
342–379（38 aa）
|
Mutation：V343W Mutation：V343W | BX7 N-(3-{[5-iodo-4-({3-[(thiophen-2-ylcarbonyl)amino]propyl}amino)pyrimidin-2-yl]amino}phenyl)pyrrolidine-1-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；18% v/v tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 2% PEG3350
|
Resolution 3.17 Å R-free 0.231 |
| 6XF3 Crystal structure of STING in complex with E7766 Deposited 2020-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Chain B
155–341（187 aa）
|
Not recorded | V5V (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-difluoro-34,39-disulfanyl-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34,39-diphosphaoctacyclo[28.6.4.1~3,36~.1~28,31~.0~4,8~.0~7,12~.0~19,24~.0~23,27~]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene 34,39-dioxide (non-preferred name) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M HEPES pH 7.5,
0.2M CaCl2,
15% (w/v) PEG 8000
|
Resolution 2.38 Å R-free 0.261 |
| 6XF4 Crystal structure of STING REF variant in complex with E7766 Deposited 2020-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Chain B
155–341（187 aa）
|
Not recorded | V5V (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-difluoro-34,39-disulfanyl-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34,39-diphosphaoctacyclo[28.6.4.1~3,36~.1~28,31~.0~4,8~.0~7,12~.0~19,24~.0~23,27~]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene 34,39-dioxide (non-preferred name) × 1 EDO 1,2-ETHANEDIOL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M HEPES pH 7.5,
0.2M CaCl2,
15% (w/v) PEG 8000
|
Resolution 2.77 Å R-free 0.271 |
| 6Y99 hSTING mutant R232K in complex with 2',3'-cGAMP Deposited 2020-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–343（204 aa）
|
Not recorded | 1SY cGAMP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M tri-Sodium Citrate dihydrate
20% (w/v) PEG 3350
|
Resolution 2.98 Å R-free 0.284 |
| 6YWA Human REF STING in complex with 3',3'-c-[2'FdAMP-2'FdAM(PS)] Deposited 2020-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–343（204 aa）
Chain B
140–343（204 aa）
|
Not recorded | GOL GLYCEROL × 1 PWB 3',3'-c-[2'FdAMP-2'FdAM(PS)] × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M Citric acid pH 5.0,
20% PEG 6000
|
Resolution 2.31 Å R-free 0.244 |
| 7MHC Structure of human STING in complex with MK-1454 Deposited 2021-04-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
154–341（188 aa）
|
Mutation：G230A, H232R, R293Q | ZEV (2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2,10-bis(sulfanyl)octahydro-2H,10H,12H-5,8-methano-2lambda~5~,10lambda~5~-furo[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1 M TRIS; 0.2 M NaCl; 28.0 w/v PEG 6K
|
Resolution 2.32 Å R-free 0.224 |
| 7OB3 hSTING in complex with 3',3'-c-di-araAMP Deposited 2021-04-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–343（204 aa）
|
Not recorded | V7E 3',3'-c-di-araAMP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；291 K；0.2 M Sodium chlorid, 0.1 M Tris pH 7.4, 30% PEG 300, 10 mM EDTA
|
Resolution 2.30 Å R-free 0.230 |
| 7Q3B Crystal structure of human STING in complex with 3'3'-c-(2'F,2'dA-isonucA)MP Deposited 2021-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–343（204 aa）
|
Not recorded | 8SC 3'3'-c-(2'F,2'dA-isonucA)MP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M Lithium acetate,
20% (w/v) PEG 3350
|
Resolution 2.56 Å R-free 0.232 |
| 7Q85 Crystal structure of human STING in complex with MD1193 Deposited 2021-11-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–343（204 aa）
|
Not recorded | 98F 9-[(1R,6R,8R,13E,15R,17R,18R)-17-(6-aminopurin-9-yl)-9,18-bis(fluoranyl)-3,12-bis(oxidanyl)-3,12-bis(oxidanylidene)-2,4,7,11,16-pentaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.3.0.0^{6,10}]octadec-13-en-8-yl]purin-6-amine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2 M Lithium acetate,
20% (w/v) PEG 3350
|
Resolution 2.36 Å R-free 0.252 |
| 7R4H phospho-STING binding to adaptor protein complex-1 Deposited 2022-02-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric |
Chain L
359–367（9 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GTP GUANOSINE-5'-TRIPHOSPHATE × 2 MG MAGNESIUM ION × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；PBS buffer
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.34 Å |
| 7SHO Crystal structure of hSTING in complex with c[2',3'-(ara-2'-G, ribo-3'-A)-MP] (RJ242) Deposited 2021-10-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
155–341（187 aa）
|
Not recorded | 9UH (2R,5R,7R,8S,10R,12aR,14R,15R,15aS,16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-2,10,15,16-tetrahydroxyoctahydro-2H,10H,12H-5,8-methano-2lambda~5~,10lambda~5~-furo[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Potassium Sodium tartrate, 20% PEG3350
|
Resolution 2.25 Å R-free 0.222 |
| 7SHP Crystal structure of hSTING in complex with c[2',3'-(ribo-2'-G, xylo-3'-A)-MP](RJ244) Deposited 2021-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Chain B
155–341（187 aa）
|
Not recorded | 9UR (2S,5R,7R,8R,10S,12aR,14R,15R,15aR,16R)-7-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-2,10,15,16-tetrahydroxyoctahydro-2H,10H,12H-5,8-methano-2lambda~5~,10lambda~5~-furo[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M potassium formate, 20% PEG3350
|
Resolution 2.20 Å R-free 0.251 |
| 7SHP Crystal structure of hSTING in complex with c[2',3'-(ribo-2'-G, xylo-3'-A)-MP](RJ244) Deposited 2021-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
155–341（187 aa）
Chain D
155–341（187 aa）
|
Not recorded | 9UR (2S,5R,7R,8R,10S,12aR,14R,15R,15aR,16R)-7-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-2,10,15,16-tetrahydroxyoctahydro-2H,10H,12H-5,8-methano-2lambda~5~,10lambda~5~-furo[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M potassium formate, 20% PEG3350
|
Resolution 2.20 Å R-free 0.251 |
| 7SII Human STING bound to both cGAMP and 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide (Compound 53) Deposited 2021-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 2 1SY cGAMP × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.45 Å |
| 7T9U Crystal structure of hSTING with an agonist (SHR169224) Deposited 2021-12-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
149–345（197 aa）
|
Not recorded | CA CALCIUM ION × 2 GD2 (3S,4S)-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-4-(prop-2-en-1-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-8-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.07M CACODYLATE PH 6.8, 0.8M CALCIUM ACETATE, 13-15% PEG8000, AND 20% GLYCEROL
|
Resolution 2.46 Å R-free 0.233 |
| 7T9V Crystal structure of hSTING with the agonist, SHR171032 Deposited 2021-12-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
149–345（197 aa）
Chain B
149–345（197 aa）
|
Not recorded | CA CALCIUM ION × 2 GC0 (3S,4S)-4-(3-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-benzimidazol-1-yl}propyl)-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-8-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；298 K；0.07M CACODYLATE PH 6.8, 0.8M CALCIUM ACETATE, 13-15% PEG8000, AND 20% GLYCEROL
|
Resolution 2.68 Å R-free 0.235 |
| 7X9P Crystal structure of human STING complexed with compound BSP17 Deposited 2022-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
150–379（230 aa）
|
Not recorded | A8A 4-[6-methoxy-5-[3-[[6-methoxy-2-(4-oxidanyl-4-oxidanylidene-butanoyl)-1-benzoselenophen-5-yl]oxy]propoxy]-1-benzoselenophen-2-yl]-4-oxidanylidene-butanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.5；293 K；PEG3350
|
Resolution 2.70 Å R-free 0.279 |
| 7X9Q Crystal structure of human STING complexed with compound BSP16 Deposited 2022-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
150–379（230 aa）
|
Not recorded | A9X (2R)-4-(5,6-dimethoxy-1-benzoselenophen-2-yl)-2-ethyl-4-oxidanylidene-butanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.5；293 K；PEG3350
|
Resolution 2.40 Å R-free 0.267 |
| 8A2H human STING in complex with 2',3'-cyclic-GMP-7-deazaphenyl-AMP Deposited 2022-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–379（240 aa）
Chain B
140–379（240 aa）
|
Not recorded | OK6 2-azanyl-9-[(1~{R},6~{R},8~{R},9~{R},10~{S},15~{R},17~{R},18~{R})-8-(4-azanyl-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-3,9,12,18-tetrakis(oxidanyl)-3,12-bis(oxidanylidene)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-1~{H}-purin-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；200mM ammonium nitrate, 20% (w/v) PEG 3350, 10mM EDTA
|
Resolution 2.69 Å R-free 0.285 |
| 8A2I human STING in complex with 2'-3'-cyclic-GMP-7-deaza(4-(2-naphthyl)phenyl)-AMP Deposited 2022-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–379（240 aa）
Chain B
140–379（240 aa）
|
Not recorded | KWF 2-azanyl-9-[(1~{R},6~{R},8~{R},9~{R},10~{S},15~{R},17~{R},18~{R})-8-[4-azanyl-5-(4-naphthalen-2-ylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,9,12,18-tetrakis(oxidanyl)-3,12-bis(oxidanylidene)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-3~{H}-purin-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；100 mM PIPES [pH 7.0], 100 mM magnesium formate dihydrate, 100 mM rubidium chloride, 25% (w/v) PEG smear high
|
Resolution 2.16 Å R-free 0.251 |
| 8A2J human STING in complex with 2'-3'-cyclic-GMP-7-deaza(4-biphenylyl)-AMP Deposited 2022-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–379（240 aa）
Chain B
140–379（240 aa）
|
Not recorded | KWO 2-azanyl-9-[(1~{R},6~{R},8~{R},9~{R},10~{S},15~{R},17~{R},18~{R})-8-[4-azanyl-5-(4-phenylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-3,9,12,18-tetrakis(oxidanyl)-3,12-bis(oxidanylidene)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-1~{H}-purin-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；100 mM citric acid, 20% (w/v) PEG 6000
|
Resolution 2.32 Å R-free 0.264 |
| 8A2K human STING in complex with 2'-3'-cyclic-GMP-7-deaza(4-[(2-naphthyloxy)methyl]phenyl)-AMP Deposited 2022-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–379（240 aa）
Chain B
140–379（240 aa）
|
Not recorded | KXD 2-azanyl-9-[(1~{R},6~{R},8~{R},9~{R},10~{S},15~{R},17~{R},18~{R})-8-[4-azanyl-5-[4-(naphthalen-1-yloxymethyl)phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]-3,9,12,18-tetrakis(oxidanyl)-3,12-bis(oxidanylidene)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-3~{H}-purin-6-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；100 mM PIPES [pH 7.0], 100 mM magnesium formate dihydrate, 100 mM rubidium chloride, 25% (w/v) PEG smear high, 10 mM EDTA, 100 mM tri-sodium citrate
|
Resolution 1.89 Å R-free 0.260 |
| 8B2J Crystal structure of human STING in complex with ADU-S100 Deposited 2022-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
138–379（242 aa）
|
Not recorded | GJF (1~{R},3~{S},6~{R},8~{R},9~{R},10~{S},12~{S},15~{R},17~{R},18~{R})-8,17-bis(6-aminopurin-9-yl)-3,12-bis(oxidanylidene)-3,12-bis(sulfanyl)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecane-9,18-diol × 1 CA CALCIUM ION × 1 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；20% PEG 3350, 0.04 M Citric acid, 0.06 M BIS-TRIS propane pH 6.4
|
Resolution 2.17 Å R-free 0.285 |
| 8B2J Crystal structure of human STING in complex with ADU-S100 Deposited 2022-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
138–379（242 aa）
|
Not recorded | CA CALCIUM ION × 1 NA SODIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；20% PEG 3350, 0.04 M Citric acid, 0.06 M BIS-TRIS propane pH 6.4
|
Resolution 2.17 Å R-free 0.285 |
| 8FLK Cryo-EM structure of STING oligomer bound to cGAMP and NVS-STG2 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | 1SY cGAMP × 2 Y6H 4-({[4-(2-tert-butyl-5,5-dimethyl-1,3-dioxan-2-yl)phenyl]methyl}amino)-3-methoxybenzoic acid × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 4.00 Å |
| 8FLM Cryo-EM structure of STING oligomer bound to cGAMP, NVS-STG2 and C53 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | Y6H 4-({[4-(2-tert-butyl-5,5-dimethyl-1,3-dioxan-2-yl)phenyl]methyl}amino)-3-methoxybenzoic acid × 2 1SY cGAMP × 2 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 2.90 Å |
| 8GJX Structure of the human STING receptor bound to 2'3'-cUA Deposited 2023-03-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
154–341（188 aa）
Chain B
154–341（188 aa）
|
Not recorded | ZNT 2'3'-cUA × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M Lithium Sulfate, 0.1 M Tris pH 8.5, 16% PEG 4000
|
Resolution 2.60 Å R-free 0.254 |
| 8GSZ Structure of STING SAVI-related mutant V147L Deposited 2022-09-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
|
Mutation：V147L Mutation：V147L | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.65 Å |
| 8GT6 human STING With agonist HB3089 Deposited 2022-09-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
|
Not recorded | WJ6 1-[(2E)-4-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-[3-(morpholin-4-yl)propoxy]-1H-benzimidazol-1-yl}but-2-en-1-yl]-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.47 Å |
| 8IK3 Structure of Stimulator of interferon genes/ligand complex Deposited 2023-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
Chain C
1–379（379 aa）
Chain D
1–379（379 aa）
Chain E
1–379（379 aa）
Chain F
1–379（379 aa）
Chain G
1–379（379 aa）
Chain H
1–379（379 aa）
|
Not recorded | 1SY cGAMP × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM HEPES, 150 mM NaCl, 1mM DTT
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 8P01 Crystal structure of human STING ectodomain in complex with BI 7446, a potent cyclic dinucleotide STING agonist with broad-spectrum variant activity for the treatment of cancer Deposited 2023-05-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
149–379（231 aa）
|
Not recorded | W78 3-[(1~{R},3~{R},6~{R},8~{R},9~{R},10~{R},12~{R},15~{R},17~{R},18~{R})-8-(6-aminopurin-9-yl)-9-fluoranyl-18-oxidanyl-3,12-bis(oxidanylidene)-3,12-bis(sulfanyl)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-6~{H}-imidazo[4,5-d]pyridazin-7-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；20% polyethelene glycol 3350, 200mM tri-sodium citrate
|
Resolution 2.09 Å R-free 0.262 |
| 8P45 Crystal structure of human STING in complex with the agonist MD1202D Deposited 2023-05-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
140–343（204 aa）
|
Not recorded | WY8 9-[(1~{S},3~{R},6~{R},8~{R},9~{R},10~{R},12~{R},15~{R},17~{R},18~{R})-8-(6-aminopurin-9-yl)-9,18-bis(fluoranyl)-3,12-bis(oxidanylidene)-3,12-bis(sulfanyl)-2,4,7,11,13-pentaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecan-17-yl]-1~{H}-purin-6-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；200 mM sodium chloride;
100 mM HEPES pH 7.5;
20 % w/v PEG 4000;
10 mM spermine, 10 mM spermidine, 10mM ornithine, 10 mM 1,4-diaminobutane
|
Resolution 3.23 Å R-free 0.259 |
| 8STH human STING with diABZI agonist 15 Deposited 2023-05-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
153–339（187 aa）
Fragment：Cyclic dinucleotide-binding domain
|
Not recorded | WWU 1-[(2E)-4-{5-carbamoyl-2-[(4-ethyl-2-methyl-1,3-oxazole-5-carbonyl)amino]-7-(3-hydroxypropoxy)-1H-benzimidazol-1-yl}but-2-en-1-yl]-2-[(4-ethyl-2-methyl-1,3-oxazole-5-carbonyl)amino]-7-methoxy-1H-benzimidazole-5-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350; ammonium tartrate
|
Resolution 1.97 Å R-free 0.247 |
| 8STI human STING with agonist XMT-1616 Deposited 2023-05-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
153–339（187 aa）
Fragment：Cyclic dinucleotide-binding domain
|
Not recorded | WX8 3-[(2E)-4-{5-carbamoyl-2-[(4-ethyl-2-methyl-1,3-oxazole-5-carbonyl)amino]-7-(3-hydroxypropoxy)-1H-benzimidazol-1-yl}but-2-en-1-yl]-2-[(4-ethyl-2-methyl-1,3-oxazole-5-carbonyl)amino]-3H-imidazo[4,5-b]pyridine-6-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；PEG 3350; ammonium tartrate
|
Resolution 1.72 Å R-free 0.257 |
| 8T5K Crystal structure of STING CTD in complex with BDW-OH Deposited 2023-06-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
154–341（188 aa）
Fragment：C-terminal domain (UNP residues 154-341)
|
Not recorded | YGI {[(4S)-8,9-dimethylthieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3-yl]sulfanyl}acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, 25% PEG3350
|
Resolution 1.95 Å R-free 0.230 |
| 8T5L Crystal structure of STING CTD in complex with 2'3'-cGAMP Deposited 2023-06-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
154–341（188 aa）
Fragment：C-terminal domain (UNP residues 154-341)
|
Not recorded | 1SY cGAMP × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, 25% PEG3350
|
Resolution 2.01 Å R-free 0.220 |
| 8YWB a protein with a ligand Deposited 2024-03-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
1–379（379 aa）
Chain D
1–379（379 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；291.15 K；Sodium phosphate monobasic, HEPES/Sodium hydroxide, Potassium phosphate dibasic
|
Resolution 2.49 Å R-free 0.306 |
| 8Z37 Crystal structure of human STING ligand binding domain. Deposited 2024-04-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
152–343（192 aa）
|
Not recorded | CL CHLORIDE ION × 2 CA CALCIUM ION × 2 Y4T (1P)-3',5-di(prop-2-en-1-yl)[1,1'-biphenyl]-2,4'-diol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；289 K；0.16 M calcium acetate, 0.08 M sodium cacodylate, pH [6.5], 14.4 % w/v PEG 8000, 20 % v/v glycerol
|
Resolution 2.40 Å R-free 0.245 |
| 9CT3 HsSTING with SR-717 and C53 Deposited 2024-07-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | V67 4,5-difluoro-2-{[6-(1H-imidazol-1-yl)pyridazine-3-carbonyl]amino}benzoic acid × 4 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.09 Å |
| 9CT4 HsSTING with diABZI and C53, curved conformation Deposited 2024-07-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | A1AZ0 1-[(2E)-4-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-1,3-benzimidazol-1-yl}but-2-en-1-yl]-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-[3-(morpholin-4-yl)propoxy]-1H-1,3-benzimidazole-5-carboxamide × 2 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.29 Å |
| 9CT5 HsSTING with diABZI and C53, together conformation Deposited 2024-07-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
Chain E
1–344（344 aa）
Chain F
1–344（344 aa）
Chain G
1–344（344 aa）
Chain H
1–344（344 aa）
|
Not recorded | 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 4 A1AZ0 1-[(2E)-4-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-1,3-benzimidazol-1-yl}but-2-en-1-yl]-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-[3-(morpholin-4-yl)propoxy]-1H-1,3-benzimidazole-5-carboxamide × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.67 Å |
| 9CT6 HsSTING with diABZI and C53, apart conformation Deposited 2024-07-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
Chain E
1–344（344 aa）
Chain F
1–344（344 aa）
Chain G
1–344（344 aa）
Chain H
1–344（344 aa）
Chain I
1–344（344 aa）
Chain J
1–344（344 aa）
Chain K
1–344（344 aa）
Chain L
1–344（344 aa）
|
Not recorded | A1AZ0 1-[(2E)-4-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-1,3-benzimidazol-1-yl}but-2-en-1-yl]-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-[3-(morpholin-4-yl)propoxy]-1H-1,3-benzimidazole-5-carboxamide × 6 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 6 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.56 Å |
| 9CUA Human STING G230A/R293Q variant bound to cGAMP Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：residues 155-341
Chain B
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：G230A/R293Q variant Mutation：G230A/R293Q variant | 1SY cGAMP × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；1.1 M Sodium/Potassium Tartrate, 0.1 M MES pH 6.0
|
Resolution 2.22 Å R-free 0.231 |
| 9CUB Human STING G230A/R293Q variant bound to diABZI-a1 Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：residues 155-341
Chain B
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：G230A/R293Q variant Mutation：G230A/R293Q variant | A1A3A 1,1'-[(2E)-but-2-ene-1,4-diyl]bis{2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-1,3-benzimidazole-5-carboxamide} × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1 M Bis-Tris pH 5.5, 0.2 M ammonium acetate, 25% (w/v) PEG 3,350
|
Resolution 1.87 Å R-free 0.287 |
| 9CUC Human STING G230A/R293Q variant bound to THIQi Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：residues 155-341
Chain B
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：G230A/R293Q variant Mutation：G230A/R293Q variant | A1A4R (3S,4S)-2-(4-tert-butyl-3-chlorophenyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1 M Bis-Tris pH 5.5, 0.2 M magnesium chloride, 25% (w/v) PEG 3,350
|
Resolution 2.10 Å R-free 0.321 |
| 9CUC Human STING G230A/R293Q variant bound to THIQi Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
155–341（187 aa）
Fragment：residues 155-341
Chain D
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：G230A/R293Q variant Mutation：G230A/R293Q variant | A1A4R (3S,4S)-2-(4-tert-butyl-3-chlorophenyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1 M Bis-Tris pH 5.5, 0.2 M magnesium chloride, 25% (w/v) PEG 3,350
|
Resolution 2.10 Å R-free 0.321 |
| 9CUC Human STING G230A/R293Q variant bound to THIQi Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain E
155–341（187 aa）
Fragment：residues 155-341
Chain F
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：G230A/R293Q variant Mutation：G230A/R293Q variant | A1A4R (3S,4S)-2-(4-tert-butyl-3-chlorophenyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1 M Bis-Tris pH 5.5, 0.2 M magnesium chloride, 25% (w/v) PEG 3,350
|
Resolution 2.10 Å R-free 0.321 |
| 9CUD Human STING G230A/R293Q variant bound to diABZI-i Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：residues 155-341
Chain B
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：G230A/R293Q variant Mutation：G230A/R293Q variant | A1A4W (2E)-1-[(2E)-4-{(2E)-5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino]-3-methyl-2,3-dihydro-1H-1,3-benzimidazol-1-yl}-2,3-dimethylbut-2-en-1-yl]-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)imino]-7-[(3-methoxyphenyl)methoxy]-3-methyl-2,3-dihydro-1H-1,3-benzimidazole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1 M Bis-Tris pH 5.5, 0.2 M magnesium chloride, 25% (w/v) PEG 3,350
|
Resolution 1.53 Å R-free 0.258 |
| 9CUE Human STING H232R variant bound to ABZI Deposited 2024-07-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
155–341（187 aa）
Fragment：residues 155-341
Chain B
155–341（187 aa）
Fragment：residues 155-341
|
Mutation：H232R variant Mutation：H232R variant | A1A4X benzyl (3-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-1,3-benzimidazol-1-yl}propyl)carbamate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；295 K；0.1 M tri-sodium citrate dihydrate pH 5.6, 20% (w/v) PEG 4,000, 20% (v/v) isopropanol
|
Resolution 1.95 Å R-free 0.334 |
| 9DAN STING oligomer bound to PI(4,5)P2 Deposited 2024-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | Y6H 4-({[4-(2-tert-butyl-5,5-dimethyl-1,3-dioxan-2-yl)phenyl]methyl}amino)-3-methoxybenzoic acid × 2 A1BBG (2R)-3-{[(S)-hydroxy{[(1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-bis(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl di[(9Z)-octadec-9-enoate] × 2 Y01 CHOLESTEROL HEMISUCCINATE × 2 1SY cGAMP × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.60 Å |
| 9DAT STING oligomer bound to PI(3,5)P2 Deposited 2024-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | Y6H 4-({[4-(2-tert-butyl-5,5-dimethyl-1,3-dioxan-2-yl)phenyl]methyl}amino)-3-methoxybenzoic acid × 2 A1BBH (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,4,6-trihydroxy-3,5-bis(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl di[(9Z)-octadec-9-enoate] × 2 Y01 CHOLESTEROL HEMISUCCINATE × 2 1SY cGAMP × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å |
| 9DAV STING oligomer bound to cGAMP and STG2 in the presence of PI4P Deposited 2024-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | Y6H 4-({[4-(2-tert-butyl-5,5-dimethyl-1,3-dioxan-2-yl)phenyl]methyl}amino)-3-methoxybenzoic acid × 2 1SY cGAMP × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 9DAW STING oligomer bound to cGAMP, C53 and PI(3,5)P2 Deposited 2024-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | A1BBH (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,4,6-trihydroxy-3,5-bis(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl di[(9Z)-octadec-9-enoate] × 2 Y01 CHOLESTEROL HEMISUCCINATE × 2 1SY cGAMP × 2 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å |
| 9JW6 STING bound with a novel small molecule agonist Deposited 2024-10-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
6–336（331 aa）
Chain B
6–336（331 aa）
Chain C
6–336（331 aa）
Chain D
6–336（331 aa）
|
Not recorded | A1EDL 4-[6-(2-chloranyl-6-cyclopropyl-phenyl)carbonylimidazo[1,5-a]pyrimidin-8-yl]-2-oxidanyl-benzoic acid × 2 A1EER [(2R)-2-dodecanoyloxy-3-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] dodecanoate × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.71 Å |
| 9K76 Crystal structure of human STING in complex with F2W Deposited 2024-10-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
153–343（191 aa）
|
Not recorded | 1T2 5-chloranyl-3-[(4-methylsulfonylphenyl)carbonylamino]-1-benzofuran-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289.15 K；0.2 M calcium acetate, 20% w/v polyethylene glycol 3350, 0.1 M sodium acetate, pH 6.0
|
Resolution 2.17 Å R-free 0.230 |
| 9KYA Crystal Structure of human STING Deposited 2024-12-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
155–341（187 aa）
|
Not recorded | CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate, pH 6.5, 14.4 % w/v PEG 8000, 20 % v/v Glycerol
|
Resolution 1.89 Å R-free 0.240 |
| 9N7F HsSTING with cGAMP/C53/DCA Deposited 2025-02-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–344（344 aa）
Chain B
1–344（344 aa）
Chain C
1–344（344 aa）
Chain D
1–344（344 aa）
|
Not recorded | 9IM 1-[(2-chloro-6-fluorophenyl)methyl]-3,3-dimethyl-2-oxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3-dihydro-1H-indole-6-carboxamide × 2 1SY cGAMP × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.93 Å |
| 9QVT Crystal structure of STING CTD in complex with potent agonist D5 Deposited 2025-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
138–379（242 aa）
|
Mutation：L139S,H232R | A1JA0 4-[6-methoxy-5-[[6-methoxy-2-(4-oxidanyl-4-oxidanylidene-butanoyl)-1-benzothiophen-5-yl]sulfanylmethylsulfanyl]-1-benzothiophen-2-yl]-4-oxidanylidene-butanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M NaNO3 (Salt)
20 %w/v PEG 3350 (Precipitant)
10 %v/v EG (Precipitant)
0.1 M BIS-TRIS prop 7.5 pH (Buffer)
|
Resolution 2.31 Å R-free 0.388 |
| 9SWM Stimulator of interferon genes protein Deposited 2025-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 5.6；20 mM MES, 150 mM NaCl, 0.001% LMNG/0.0001% CHS, 0.0001%GDN
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.38 Å |
| 9SWQ Stimulator of interferon genes protein mutant - I165H Deposited 2025-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.31 Å |
| 9SWR Stimulator of interferon genes protein mutant - W119K M120K Deposited 2025-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
Chain C
1–379（379 aa）
Chain D
1–379（379 aa）
Chain E
1–379（379 aa）
Chain F
1–379（379 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.86 Å |
| 9SWS Stimulator of interferon genes protein mutant - D319K D320K Deposited 2025-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–379（379 aa）
Chain B
1–379（379 aa）
Chain C
1–379（379 aa）
Chain D
1–379（379 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.04 Å |
| 9WH8 Crystal Structure of Human STING bound to diABZI3 Deposited 2025-08-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
154–341（188 aa）
|
Not recorded | A1AZ0 1-[(2E)-4-{5-carbamoyl-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-methoxy-1H-1,3-benzimidazol-1-yl}but-2-en-1-yl]-2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-7-[3-(morpholin-4-yl)propoxy]-1H-1,3-benzimidazole-5-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；0.1M Imidazole pH6.5, 1M Sodium acetate trihydrate
|
Resolution 1.90 Å R-free 0.263 |
84 other PDB entries and 90 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | STING_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain D； PDBConstruct 2–226； UniProt 155–379 Author chain E； PDBConstruct 2–226； UniProt 155–379 |
